Amgen Plows Ahead With Costly, Highly Toxic Cancer Dosing Despite FDA Challenge

The FDA told Amgen to test whether a quarter-dose of its lung cancer drug worked as well as the amount recommended on the product label. It did and with fewer side effects. But Amgen is sticking to the higher dose — which earns it an additional $180,000 a year per patient…

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button